Integrated Investment Consultants LLC Sells 1,391 Shares of Amgen Inc. $AMGN

Integrated Investment Consultants LLC decreased its stake in Amgen Inc. (NASDAQ:AMGN) by 40.4% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,051 shares of the medical research company’s stock after selling 1,391 shares during the quarter. Integrated Investment Consultants LLC’s holdings in Amgen were worth $579,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the stock. Tcfg Wealth Management LLC boosted its stake in shares of Amgen by 525.8% in the 3rd quarter. Tcfg Wealth Management LLC now owns 6,283 shares of the medical research company’s stock valued at $1,773,000 after purchasing an additional 5,279 shares in the last quarter. Livforsakringsbolaget Skandia Omsesidigt grew its holdings in shares of Amgen by 2.5% in the 3rd quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 57,618 shares of the medical research company’s stock worth $16,251,000 after purchasing an additional 1,400 shares during the last quarter. U S Wealth Group LLC. increased its position in shares of Amgen by 7.0% during the 3rd quarter. U S Wealth Group LLC. now owns 8,381 shares of the medical research company’s stock worth $2,365,000 after purchasing an additional 549 shares in the last quarter. Apexium Financial LP lifted its holdings in Amgen by 1.6% during the 3rd quarter. Apexium Financial LP now owns 2,582 shares of the medical research company’s stock valued at $729,000 after purchasing an additional 40 shares during the last quarter. Finally, Peloton Wealth Strategists lifted its holdings in Amgen by 0.4% during the 3rd quarter. Peloton Wealth Strategists now owns 11,525 shares of the medical research company’s stock valued at $3,252,000 after purchasing an additional 47 shares during the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

AMGN has been the topic of several research analyst reports. Morgan Stanley upped their price objective on shares of Amgen from $304.00 to $309.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 4th. Wall Street Zen cut shares of Amgen from a “buy” rating to a “hold” rating in a research note on Saturday, February 21st. Daiwa Securities Group boosted their target price on Amgen from $370.00 to $410.00 and gave the stock an “outperform” rating in a report on Tuesday, February 10th. Argus increased their price target on Amgen from $360.00 to $400.00 and gave the stock a “buy” rating in a research report on Friday, February 6th. Finally, Royal Bank Of Canada raised their price target on Amgen from $335.00 to $360.00 and gave the company an “outperform” rating in a report on Wednesday, February 4th. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, thirteen have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $354.00.

Amgen Trading Down 1.4%

AMGN opened at $361.13 on Wednesday. Amgen Inc. has a 1-year low of $261.43 and a 1-year high of $391.29. The stock has a market capitalization of $194.67 billion, a PE ratio of 25.38, a PEG ratio of 3.63 and a beta of 0.45. The company has a current ratio of 1.14, a quick ratio of 0.90 and a debt-to-equity ratio of 5.78. The firm has a 50-day moving average price of $359.26 and a two-hundred day moving average price of $326.77.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The company had revenue of $9.87 billion for the quarter, compared to analyst estimates of $9.46 billion. During the same period in the prior year, the business earned $5.31 earnings per share. Amgen’s quarterly revenue was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, equities analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be issued a dividend of $2.52 per share. The ex-dividend date of this dividend is Friday, May 15th. This represents a $10.08 annualized dividend and a yield of 2.8%. Amgen’s dividend payout ratio is currently 70.84%.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen reported stronger-than-expected results and raised FY guidance, supporting fundamentals and cash flow — a key reason some investors remain constructive. MarketBeat Earnings & Guidance
• Positive Sentiment: Analysts lifted Amgen’s fair-value estimate on growing confidence in execution and the MariTide obesity program, which boosts upside expectations if clinical/exclusivity risks are managed. Yahoo: Narrative Shifting
• Positive Sentiment: Large investor interest: Ken Fisher’s firm increased its Amgen stake, a vote of confidence from a prominent institutional investor. Yahoo: Ken Fisher Doubles Position
• Neutral Sentiment: Amgen is being watched by retail and professional traders (trending coverage), which can amplify moves but doesn’t by itself change fundamentals. Zacks: Trending Stock
• Neutral Sentiment: Reported short-interest data in recent feeds appears inconsistent/zeroed out and is not signaling a clear squeeze or covering dynamic at this time.
• Neutral Sentiment: Amgen’s shares were reported to outperform many peers on a relative-basis despite the intraday decline, indicating sector/stock-specific flows rather than a company-specific collapse. MarketWatch: Outperforms Peers
• Negative Sentiment: Amgen (with peers) is reportedly joining a drug-discount initiative (TrumpRx), which could pressure pricing and margins for certain products if discounts are material. Benzinga: TrumpRx Participation
• Negative Sentiment: Analyst upgrades and MariTide optimism are tempered by exclusivity and long-term earnings debate — unresolved regulatory/IP questions could cap upside until clearer trial and exclusivity outcomes arrive. Yahoo: Exclusivity Concerns

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.